Abstract
Blocking IL-6 pathways with sarilumab, a fully human anti-IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used "off-label" sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
MeSH terms
-
Aged
-
Anti-Infective Agents / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Azithromycin / therapeutic use
-
COVID-19 / physiopathology
-
COVID-19 Drug Treatment*
-
Comorbidity
-
Critical Illness
-
Cytokine Release Syndrome / drug therapy*
-
Cytokine Release Syndrome / physiopathology
-
Humans
-
Hydroxychloroquine / therapeutic use
-
Interleukin-6 / antagonists & inhibitors*
-
Male
-
Middle Aged
-
RNA, Viral
-
Respiration, Artificial / statistics & numerical data
-
Retrospective Studies
-
SARS-CoV-2
Substances
-
Anti-Infective Agents
-
Antibodies, Monoclonal, Humanized
-
Interleukin-6
-
RNA, Viral
-
Hydroxychloroquine
-
Azithromycin
-
sarilumab